We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

18 hedge funds and large institutions have $7.39M invested in Oruka Therapeutics in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

20% more capital invested

Capital invested by funds: $6.17M → $7.39M (+$1.22M)

13% more funds holding

Funds holding: 16 → 18 (+2)

0.02% more ownership

Funds ownership: 0.2% → 0.21% (+0.02%)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$121K
2
PAM
Panagora Asset Management
Massachusetts
+$54.4K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$13.9K
4
VF
Virtu Financial
New York
+$8.11K
5
Northern Trust
Northern Trust
Illinois
+$4.05K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$144K
2
Deutsche Bank
Deutsche Bank
Germany
-$112K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$13.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$1.97M – – –
Franklin Resources
2
Franklin Resources
California
$1.67M – – –
VMI
3
VHCP Management II
New York
$1.46M – – –
TCM
4
Tekla Capital Management
Massachusetts
$1.11M – – –
RA
5
Royce & Associates
New York
$447K +$121K +417 +38%
Renaissance Technologies
6
Renaissance Technologies
New York
$175K -$144K -496 -45%
Vanguard Group
7
Vanguard Group
Pennsylvania
$138K -$13.9K -48 -9%
SM
8
Sabby Management
Florida
$138K – – –
ACP
9
Aveo Capital Partners
Colorado
$126K – – –
PAM
10
Panagora Asset Management
Massachusetts
$56K +$54.4K +188 New
VF
11
Virtu Financial
New York
$32K +$8.11K +28 +35%
Northern Trust
12
Northern Trust
Illinois
$19K +$4.05K +14 +27%
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
$14K – – –
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$14K +$13.9K +48 New
UBS Group
15
UBS Group
Switzerland
$7K +$2.03K +7 +37%
Deutsche Bank
16
Deutsche Bank
Germany
$6K -$112K -386 -94%
BlackRock
17
BlackRock
New York
$1K – – –
Bank of America
18
Bank of America
North Carolina
$1K +$290 +1 +33%

ORKA Hedge Fund Activity: Q4 2017 in Review

18 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2017, worth a combined $7.39M — up 20% from $6.17M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ORKA positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Royce & Associates, adding an estimated $121K. The largest seller was Renaissance Technologies, cutting an estimated $144K.

  • 18 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2017, up from 16 in Q3 2017.
  • Funds reported $7.39M of Oruka Therapeutics stock for Q4 2017, up 20% quarter-over-quarter.
  • 2 funds opened new Oruka Therapeutics positions in Q4 2017 and 0 closed out, a net change of +2 holders.
  • The largest Oruka Therapeutics buyer in Q4 2017 was Royce & Associates, an estimated $121K added.
  • The largest Oruka Therapeutics seller in Q4 2017 was Renaissance Technologies, an estimated $144K sold.

Based on aggregated 13F filings for Q4 2017.